Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond

Area of Science:

• Innate immunity
• Complement system biology
• Hematologic diseases

Background:

• Excessive complement activation due to genetic variants or autoantibodies causes various human diseases.
• Paroxysmal nocturnal hemoglobinuria (PNH) is a key model for complement activation and inhibition.
• Several complement inhibitors are now approved or under investigation for hematologic conditions.

Purpose of the Study:

• To review the current knowledge on targeting the complement system in hematologic diseases.
• To discuss complement biology, activation, and therapeutic inhibition strategies.
• To explore emerging applications of complement inhibitors in hematology.

Main Methods:

• Review of scientific literature on complement system and its role in hematologic diseases.
• Analysis of approved and investigational complement inhibitors.
• Focus on therapeutic strategies for PNH, cold agglutinin disease, and transplantation-associated thrombotic microangiopathy.

Main Results:

• Approved therapies include C5 inhibitors (eculizumab, ravulizumab) and a C3 inhibitor (pegcetacoplan) for PNH.
• Complement inhibition shows efficacy in cold agglutinin disease (sutimlimab, pegcetacoplan).
• Investigational therapies target various complement pathways for other hematologic disorders.

Conclusions:

• Personalized selection of complement inhibitors is crucial for optimal patient outcomes.
• Complement inhibition holds promise for treating a broader range of hematologic diseases.
• Continued research into novel complement-targeting agents is essential for advancing hematology.